Extension Of Eliquis’ Indication Will See It Face Off Against Xarelto And Pradaxa In Europe
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s top drug regulator recommended an additional indication for Bristol-Myers Squibb/ Pfizer’s Eliquis for AF, setting the stage there for a showdown with Bayer/J&J’s Xarelto and Boehringer Ingelheim’s Pradaxa.